will buy Santarus Inc for about $2.6 billion, gaining two new gastroenterology drugs to strengthen its leading presence in that market and sending its shares 10 percent higher. The deal brings together two companies seen as having complementary product portfolios and will mark Salix's biggest acquisition in at least the last ten years - a period when it made as many as six. In addition to the two gastroenterology drugs, biotech firm Santarus has two type 2 diabetes drugs and a cholesterol drug on the market. via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment